-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A study published in the journal AIDS shows that long-term administration of ilotinib reduces LDL-C and non-HDL-C levels and helps more people with HIV achieve recommended lipid management goals without serious adverse events
Long-term use of eloyumab reduces LDL-C and non-HDL-C levels and helps more HIV-positive individuals achieve recommended lipid management goals without serious adverse events Long-term use of eloyumab Antibiotics lower LDL-C and non-HDL-C levels and help more HIV-positive people achieve recommended lipid management goals without serious adverse events
People living with HIV are at increased risk of developing atherosclerotic cardiovascular disease , and the suboptimal response to statins in this population may stem from some antiretroviral therapy (ART)
A cross-country, placebo-controlled, double-blind, randomized, phase 3 clinical trial on an increasing risk of atherosclerotic cardiovascular disease
Results of the study showed that of 467 double-blind randomised participants, 451 (96.
Original source:
Original source:Boccara F, Caramelli B, Calmy A, Kumar P, et al.
Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period
leave a comment here
